摘要
近年来,乳腺癌新辅助治疗逐渐开始成为研究重点。新辅助治疗是在术前对患者进行系统治疗,相同方案和疗程的新辅助治疗与辅助治疗的效果是一样的。乳腺癌新辅助治疗方案的选择与分子分型密切相关,临床工作中,需要根据各型乳腺癌的分子生物学及临床特征选择合适的治疗方案。本文就不同分子分型乳腺癌的新辅助治疗进展进行综述。
In recent years, the neoadjuvant therapy of breast cancer has gradually begun to become the focus of research. Neoadjuvant therapy is the systematic treatment of patients before surgery, and the effect of neoadjuvant therapy with the same regimen and course is the same as adjuvant therapy. The selection of neoadjuvant therapy for breast cancer is closely related to molecular classification. In clinical work, it is necessary to choose appropriate treatment options according to the molecular biology and clinical characteristics of each type of breast cancer. This review summarizes the pro-gress of neoadjuvant therapy in breast cancer with different molecular types.
出处
《临床医学进展》
2023年第10期15959-15963,共5页
Advances in Clinical Medicine
